Mylan stock bounces back from early losses after CEO blames FDA for drug delays

Earnings


Mylan’s stock bounced back in midday trading Wednesday from lower-than-expected second quarter earnings after the company’s management said its generic drug Advair is not being delayed by further FDA-required studies.

After shares of the drug-maker dropped as far as 8 percent in premarket trading, Mylan’s CEO Heather Bresch clarified on a call with investors that delaying Advair’s launch to 2018 was due to the Food and Drug Administration reorganizing and changing its priorities.

“We see the administration as the barrier, and not the science,” Bresch said.

Mylan’s second-quarter earnings report missed estimates in what Bresch called “a tough quarter,” before adding more optimistically that the company is “managing for the long term.” Bresch believes the poor quarterly result was not a “permanent hit” but rather “a deferred one.”

The company reported total revenue of $2.96 billion and earnings per share of $1.10, missing estimates of $3.03 billion in revenues and EPS of $1.16, according to analysts surveyed by Thomson Reuters.

Mylan is coping with declining profitability and it adjusted annual earnings forecasts downward. An August 2016 report by the Government Accountability Office found that U.S. generic drug prices have been declining since 2010.

“To say that times are changing would be an understatement,” Besch said.

The competitiveness of the market has been a flash point for generic drug-makers, as Teva Pharmaceutical’s interim CEO Yitzhak Peterburg blamed his company’s recent poor performance on saturation.



Source link

Products You May Like

Articles You May Like

Looking to buy a used car? Experts say ask these 5 questions first
BTS mastermind Bang Si-hyuk, Jeff Bezos agree on this success strategy
Founder of bottled water Nongfu Spring becomes China’s richest man
Royal family faces nearly $45 million shortfall due to the coronavirus
Game reserves in KwaZulu-Natal, South Africa: Safaris and eco-tourism

Leave a Reply

Your email address will not be published. Required fields are marked *